“…Another example of this approach 68 Eudragit® E100, or Eudragit® S100, 69 selfemulsifying solid dispersion of isradipine with poloxamer 407 which was formulated into hypromellose controlled-release tablet, 70 and penta-ethyl ester prodrug of diethylenetriamine pentaacetic acid with blends of polyvinylpyrrolidone (PVP), Eudragit® RL PO and a-tocopherol. 71 New polymers or new polymer combinations Improve stability or further tailor release kinetics and/or better maintain supersaturation with the goal to improve absorption or bioavailability…”